Abstract
Colchicine has recently gained considerable attention in the field of cardiovascular research, after a number of studies showed that it may be of use in several settings of cardiovascular disease, including chronic coronary artery disease and following stent implantation. Its unique anti-inflammatory mechanism of action makes it safe to use in patients with cardiovascular disease, unlike most – if not all – currently available antiinflammatory agents. While its prophylactic and therapeutic value is well-established in certain conditions involving an acute inflammatory response, e.g. pericarditis, in other conditions, including coronary artery disease and heart failure, which are associated with a chronic low-grade inflammatory state, the evidence regarding its potential use remains sparse. In this concise review, we present key features of this drug and the rationale for colchicine therapy, in the context of acute and chronic coronary artery disease, as well as in ischemic heart failure and critically examine the evidence concerning a possible future role of colchicine treatment in these conditions.
Keywords: Inflammation, treatment, ischemic, drug, pharmacotherapy.
Current Medicinal Chemistry
Title:Colchicine in Coronary Artery Disease: An Old Acquaintance in New Attire?
Volume: 22 Issue: 36
Author(s): Georgios Giannopoulos, Christos Angelidis, Nikolaos Papoutsidakis, Vasiliki Panagopoulou, Michael W. Cleman, John Lekakis and Spyridon Deftereos
Affiliation:
- ,0
Keywords: Inflammation, treatment, ischemic, drug, pharmacotherapy.
Abstract: Colchicine has recently gained considerable attention in the field of cardiovascular research, after a number of studies showed that it may be of use in several settings of cardiovascular disease, including chronic coronary artery disease and following stent implantation. Its unique anti-inflammatory mechanism of action makes it safe to use in patients with cardiovascular disease, unlike most – if not all – currently available antiinflammatory agents. While its prophylactic and therapeutic value is well-established in certain conditions involving an acute inflammatory response, e.g. pericarditis, in other conditions, including coronary artery disease and heart failure, which are associated with a chronic low-grade inflammatory state, the evidence regarding its potential use remains sparse. In this concise review, we present key features of this drug and the rationale for colchicine therapy, in the context of acute and chronic coronary artery disease, as well as in ischemic heart failure and critically examine the evidence concerning a possible future role of colchicine treatment in these conditions.
Export Options
About this article
Cite this article as:
Giannopoulos Georgios, Angelidis Christos, Papoutsidakis Nikolaos, Panagopoulou Vasiliki, Cleman W. Michael, Lekakis John and Deftereos Spyridon, Colchicine in Coronary Artery Disease: An Old Acquaintance in New Attire?, Current Medicinal Chemistry 2015; 22(36) . https://dx.doi.org/10.2174/0929867322666151015120458
DOI https://dx.doi.org/10.2174/0929867322666151015120458 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Anti-Seizure Medications and Estradiol for Neuroprotection in Epilepsy: The 2013 Update
Recent Patents on CNS Drug Discovery (Discontinued) Translational Multimodality Neuroimaging
Current Drug Targets Synthesis and Biological Evaluation of N-(Alkyl)-2-Thiophen-2-Ylacetamides Series As A New Class of Antitubercular Agents
Letters in Drug Design & Discovery Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema
Current Drug Safety Is Targeting microRNAs the Philosopher’s Stone for Vascular Disease?
Current Vascular Pharmacology Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Pulmonary Arterial Hypertension: Need to Treat
Inflammation & Allergy - Drug Targets (Discontinued) Getting Patients to Target- Implementing the Guidelines
Current Vascular Pharmacology Use of Bipolar Radiofrequency Catheter Ablation in the Treatment of Cardiac Arrhythmias
Current Cardiology Reviews Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Modulation of P2 Receptors on Pancreatic β-cells by Agonists and Antagonists: A Molecular Target for Type 2 Diabetes Treatment
Current Diabetes Reviews Recent Applications of Peanut Phytoalexins
Recent Patents on Food, Nutrition & Agriculture Wharton's Jelly Mesenchymal Stem Cell Response on Chitosan-graft-poly (ε-caprolactone) Copolymer for Myocardium Tissue Engineering
Current Pharmaceutical Design Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews Effects of Statins on Bone Markers, Bone Mineral Density and Fractures. Possible Role in Osteoporosis Treatment
Current Pharmaceutical Analysis The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
Current Cardiology Reviews Oral Antidiabetic Agents: Anti-Atherosclerotic Properties Beyond Glucose Lowering?
Current Pharmaceutical Design CREG: A Possible Candidate for Both Prevention and Treatment of Proliferative Vascular Disease
Current Molecular Medicine Applied Proteomics in Companion Animal Medicine
Current Proteomics